Skip to main content
SpringerLink
Log in

Clinical Pharmacology and Therapeutics of Antidepressants

  • Chapter
Pharmacotherapy of Depression

Abstract

An understanding of the clinical pharmacology of antidepressant agents is essential for optimal prescribing. This chapter outlines general principles that influence prescribing, then discusses specific subgroups of antidepressants. There is no generally accepted classification scheme for antidepressants; current groupings reflect marketing practices, the history of drug development, and pharmacological effects. We use the following terms in our discussion: selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), cyclic antidepressants, mixed action agents, selective norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and alternative (nontra-ditional) antidepressants. Readers should keep in mind, however, that we have chosen a compromise classification system that is based on terms commonly used in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Richelson, E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmocol Exp Ther 1984; 230: 94–102.

    CAS  Google Scholar 

  2. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114: 559–565.

    Article  CAS  Google Scholar 

  3. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 1305–1322.

    PubMed  CAS  Google Scholar 

  4. Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol Bull 2002; 36: 133–149.

    PubMed  Google Scholar 

  5. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003; 64 Suppl 13: 5–12.

    Google Scholar 

  6. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457–494.

    Article  PubMed  Google Scholar 

  7. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998; 59: 85–93.

    Article  PubMed  CAS  Google Scholar 

  8. Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm 2001; 108: 707–716.

    Article  PubMed  CAS  Google Scholar 

  9. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60 Suppl 4:4–11; discussion 12–13.

    Google Scholar 

  10. Sampson SM. Treating depression with selective serotonin reuptake inhibitors: a practical approach. Mayo Clin Proc 2001; 76: 739–744.

    Article  PubMed  CAS  Google Scholar 

  11. Goldberg JF. New drugs in psychiatry. Emerg Med Clin North Am 2000; 18:211–231, viii.

    Google Scholar 

  12. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders— I. Basic pharmacology. J Psychopharmacol (Oxf) 1998; 12: S5–S20.

    CAS  Google Scholar 

  13. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992; 31: 997–1000.

    Article  PubMed  CAS  Google Scholar 

  14. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40–44.

    PubMed  Google Scholar 

  15. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197–204.

    Article  PubMed  CAS  Google Scholar 

  16. Uhr M, Graucer MT. abc1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37: 179–185.

    Article  PubMed  Google Scholar 

  17. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol 2001; 41: 708–714.

    Article  PubMed  CAS  Google Scholar 

  18. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003; 160: 734–740.

    Article  PubMed  Google Scholar 

  19. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57: 9–13.

    PubMed  CAS  Google Scholar 

  20. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002; 159: 1702–1710.

    Article  PubMed  Google Scholar 

  21. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7: 24S–35S.

    Article  PubMed  CAS  Google Scholar 

  22. Benamansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22: 6766–6772.

    Google Scholar 

  23. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248–251.

    Article  PubMed  CAS  Google Scholar 

  24. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15: 217–222.

    Article  PubMed  CAS  Google Scholar 

  25. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154: 37–43.

    PubMed  CAS  Google Scholar 

  26. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594–1597.

    Article  PubMed  CAS  Google Scholar 

  27. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19: 177–182.

    Article  PubMed  CAS  Google Scholar 

  28. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1725–1727.

    Article  PubMed  CAS  Google Scholar 

  29. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 2001; 158: 2080–2082.

    Article  PubMed  CAS  Google Scholar 

  30. Wu S, Comings DE. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet 1999; 9: 105–106.

    Article  PubMed  CAS  Google Scholar 

  31. Nishiguchi N, Shirakawa O, Ono H, et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet 2002; 114: 423–425.

    Article  PubMed  Google Scholar 

  32. Isaac MT, Tome MB. Pindolol-paroxetine combination. Am J Psychiatry 1997; 154: 1790–1791.

    PubMed  CAS  Google Scholar 

  33. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998; 59: 16–23.

    PubMed  CAS  Google Scholar 

  34. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d’Experimentation Psychopharmacologique. Am J Psychiatry 1998; 155: 1346–1351.

    PubMed  CAS  Google Scholar 

  35. Palacios JM, Waeber C, Mengod G, et al. Molecular neuroanatomy of 5-HT receptors. In: Fozard JR, Saxena PR, eds. Serotonin: molecular biology, receptors and functional effects. Basel, Switzerland: Birhauser, 1991: 5–20.

    Chapter  Google Scholar 

  36. Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59 Suppl 4: 5–14.

    PubMed  CAS  Google Scholar 

  37. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: interactions and therapeutic uses. Br J Psychiatry 1995; 167: 575–580.

    Article  PubMed  CAS  Google Scholar 

  38. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996; 57: 17–25.

    PubMed  CAS  Google Scholar 

  39. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–320.

    PubMed  CAS  Google Scholar 

  40. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 1998; 13 Suppl 5: S35–S43.

    Google Scholar 

  41. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998; 22: 325–333.

    Article  PubMed  CAS  Google Scholar 

  42. Johnson MD, Newkirk G, White JR, Jr. Clinically significant drug interactions. Postgrad Med 1999; 105:193–195, 200, 205–206 passim.

    Google Scholar 

  43. Rickels K. Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 Suppl B:9–12.

    PubMed  Google Scholar 

  44. Frazer A. Antidepressants. J Clin Psychiatry 1997; 58: 9–25.

    PubMed  CAS  Google Scholar 

  45. Benbow SJ, Gill G. Drug points: paroxetine and hepatotoxicity. Br Med J 1997; 314: 1387.

    Article  CAS  Google Scholar 

  46. Cai Q, Benson MA, Talbot TJ, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999; 74: 692–694.

    Article  PubMed  CAS  Google Scholar 

  47. Garcia-Pando A, Garcia del Pozo J, Sanchez A, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63: 135–137.

    Article  CAS  Google Scholar 

  48. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol (Oxf) 1998; 12: 192–214.

    Article  CAS  Google Scholar 

  49. Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand 2001; 104: 84–91.

    Article  PubMed  CAS  Google Scholar 

  50. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377–389.

    Article  PubMed  CAS  Google Scholar 

  51. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549–550.

    Article  PubMed  CAS  Google Scholar 

  52. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry 1994; 151: 1642–1645.

    PubMed  CAS  Google Scholar 

  53. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–210.

    PubMed  CAS  Google Scholar 

  54. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991; 51: 267–285.

    Google Scholar 

  55. Tollefson GD, Rampey AH, Jr., Beasley CM, Jr., Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163–169.

    PubMed  CAS  Google Scholar 

  56. Muller-Oerlinghausen B, Berghofer A. Antidepressants and suicidal risk. J Clin Psychiatry 1999; 60 Suppl 2:94–99; discussion 111–116.

    Google Scholar 

  57. Tueth MJ. Revisiting fluoxetine (Prozac) and suicidal preoccupations. J Emerg Med 1994; 12: 685–687.

    Article  PubMed  CAS  Google Scholar 

  58. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–713.

    PubMed  CAS  Google Scholar 

  59. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–221.

    Article  PubMed  CAS  Google Scholar 

  60. Dams R, Benijts TH, Lambert WE, et al. A fatal case of serotonin syndrome after combined moclobemide and citalopram intoxication. J Anal Toxicol 2001; 25: 147–151.

    PubMed  CAS  Google Scholar 

  61. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 1281–1285.

    Article  PubMed  CAS  Google Scholar 

  62. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 957–969.

    Google Scholar 

  63. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl) 2001; 156: 73–78.

    Article  CAS  Google Scholar 

  64. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother 2002; 36:1558–1563.

    Article  PubMed  Google Scholar 

  65. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170–1176.

    PubMed  CAS  Google Scholar 

  66. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol 2000; 23: 90–97.

    Article  PubMed  CAS  Google Scholar 

  67. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61: 37–41.

    PubMed  CAS  Google Scholar 

  68. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother 1996; 30: 1232–1234.

    PubMed  CAS  Google Scholar 

  69. Balon R, Yeragani VK, Pohl R, et al. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209–212.

    PubMed  CAS  Google Scholar 

  70. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55: 406–413.

    PubMed  CAS  Google Scholar 

  71. Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther 1996; 22: 209–217.

    Article  PubMed  CAS  Google Scholar 

  72. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67–85.

    Article  PubMed  CAS  Google Scholar 

  73. Fava M, Rankin MA. Sexual functioning and SSRIs. J Clin Psychiatry 2002; 63: 13–16.

    Article  PubMed  Google Scholar 

  74. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23: 176–194.

    Article  PubMed  CAS  Google Scholar 

  75. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetineinduced sexual dysfunction. J Clin Psychiatry 1990; 51: 25–27.

    PubMed  CAS  Google Scholar 

  76. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1993; 54: 71.

    PubMed  CAS  Google Scholar 

  77. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000; 61 Suppl 11: 28–36.

    Google Scholar 

  78. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenfalin in antidepressant-induced sexual dysfunction. Psychother Psychosom 1998; 67: 328–331.

    Article  PubMed  CAS  Google Scholar 

  79. Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ. Sildenafil for sexual dysfunction in women taking antidepressants. Am J Psychiatry 1999; 156: 1664.

    PubMed  CAS  Google Scholar 

  80. Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002; 60: 58–66.

    Article  PubMed  Google Scholar 

  81. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54: 459–465.

    PubMed  CAS  Google Scholar 

  82. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152: 1514–1516.

    PubMed  CAS  Google Scholar 

  83. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol (Oxf) 1998; 12: 305–313.

    Article  CAS  Google Scholar 

  84. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic critieria. J Psychiatry Neurosci 2000; 25: 255–261.

    PubMed  CAS  Google Scholar 

  85. DeBattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal [letter]. Am J Psychiatry 1995; 152: 1235–1236.

    PubMed  CAS  Google Scholar 

  86. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59: 42–48.

    PubMed  CAS  Google Scholar 

  87. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet 1996; 348: 339–340.

    PubMed  CAS  Google Scholar 

  88. Glassman AH. Citalopram toxicity. Lancet 1997; 350: 818.

    Article  PubMed  CAS  Google Scholar 

  89. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609–610.

    CAS  Google Scholar 

  90. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–262.

    Article  PubMed  CAS  Google Scholar 

  91. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889–1895.

    Article  PubMed  Google Scholar 

  92. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000; 61: 821–827.

    Article  PubMed  CAS  Google Scholar 

  93. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58: 39–47.

    PubMed  CAS  Google Scholar 

  94. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60: 101–106.

    Article  PubMed  CAS  Google Scholar 

  95. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374–379.

    Article  PubMed  CAS  Google Scholar 

  96. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368–1371.

    PubMed  CAS  Google Scholar 

  97. Davidson JRT. Pharmacology of social anxiety disorder. J Clin Psychiatry 1998; 59: 47–51.

    Article  CAS  Google Scholar 

  98. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002; 63: 66–74.

    Article  PubMed  CAS  Google Scholar 

  99. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry 1990; 147: 876–881.

    PubMed  CAS  Google Scholar 

  100. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria: Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332: 1529–1534.

    Article  PubMed  CAS  Google Scholar 

  101. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350–357.

    Article  PubMed  CAS  Google Scholar 

  102. Davidson JRT. Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry 1997; 58: 29–32.

    PubMed  Google Scholar 

  103. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61: 81–110.

    Article  PubMed  CAS  Google Scholar 

  104. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–709.

    Article  PubMed  CAS  Google Scholar 

  105. Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62 Suppl 20: 26–31.

    Google Scholar 

  106. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143–153.

    Article  PubMed  CAS  Google Scholar 

  107. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993; 129: 175–181.

    Google Scholar 

  108. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000; 157: 344–350.

    Article  PubMed  CAS  Google Scholar 

  109. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992; 43: 11–23.

    Article  PubMed  Google Scholar 

  110. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol (Oxf) 1998; 12: S99–S111.

    CAS  Google Scholar 

  111. Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 1998; 155: 543–547.

    PubMed  CAS  Google Scholar 

  112. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1998; 59: 279–288.

    Article  PubMed  CAS  Google Scholar 

  113. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995; 56: 52–55.

    PubMed  CAS  Google Scholar 

  114. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958; 115: 459–464.

    PubMed  CAS  Google Scholar 

  115. Klerman GL, Cole JP. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17: 101–141.

    PubMed  CAS  Google Scholar 

  116. Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose: a review. JAMA 1987; 257: 521–526.

    CAS  Google Scholar 

  117. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 1999; 19: 373–409.

    Article  PubMed  CAS  Google Scholar 

  118. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 31: 691–698.

    Article  PubMed  CAS  Google Scholar 

  119. Blackwell B. Adverse effects of antidepressant drugs; part 1: MAOIs and tricyclics. Drugs 1981; 21: 201–219.

    Article  CAS  Google Scholar 

  120. Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowers MB, Jr. Major adverse reactions during desipramine treatment: relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics. Arch Gen Psychiatry 1982; 39: 1055–1061.

    Article  PubMed  CAS  Google Scholar 

  121. Glassman AH, Bigger JT, Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981; 38: 815–820.

    Article  PubMed  CAS  Google Scholar 

  122. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998; 13: S25–S30.

    Article  PubMed  Google Scholar 

  123. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994; 55 Suppl A:83–87; discussion 88–89, 98–100.

    Google Scholar 

  124. Vohra J, Burrows GD, Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med 1975; 5: 7–11.

    Article  PubMed  CAS  Google Scholar 

  125. Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine-and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol 1981; 1: 316–319.

    Article  PubMed  CAS  Google Scholar 

  126. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58–77.

    Article  PubMed  CAS  Google Scholar 

  127. Maltzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry 1937; 93: 1231–1238.

    Google Scholar 

  128. Williams RB, Jr., Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann Intern Med 1971; 74: 395–398.

    PubMed  Google Scholar 

  129. Bigger JT, Jr., Giardina EGV, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977; 296: 206–208.

    Article  PubMed  CAS  Google Scholar 

  130. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44: 273–275.

    Article  PubMed  CAS  Google Scholar 

  131. Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. Am J Psychiatry 1991; 148: 1601.

    PubMed  CAS  Google Scholar 

  132. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412.

    Article  Google Scholar 

  133. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227–233.

    Article  Google Scholar 

  134. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Is doxepin a safer tricyclic for the heart? J Clin Psychiatry 1991; 52: 338–341.

    PubMed  CAS  Google Scholar 

  135. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder. a controlled trial. Br J Psychiatry 1987; 151: 107–112.

    Article  PubMed  CAS  Google Scholar 

  136. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med 1985; 14: 1–9.

    Article  PubMed  CAS  Google Scholar 

  137. Kulig K, Rumack BH, Sullivan JB, Jr., et al. Amoxapine overdose: coma and seizures without cardiotoxic effects. JAMA 1982; 248: 1092–1094.

    CAS  Google Scholar 

  138. Litovitz TL, Troutman WG. Amoxapine overdose: seizures and fatalities. JAMA 1983; 250: 1069–1071.

    Article  PubMed  CAS  Google Scholar 

  139. Knudsen K, Heath A. Effects of self poisoning with maprotiline. Br Med J (Clin Res Ed) 1984; 288: 601–603.

    Article  CAS  Google Scholar 

  140. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993; 150: 571–577.

    PubMed  CAS  Google Scholar 

  141. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 2001; 178: 129–144.

    Article  PubMed  CAS  Google Scholar 

  142. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry 1999; 33: 323–327.

    Article  PubMed  CAS  Google Scholar 

  143. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants: Danish University Antidepressant Group. Psychopharmacol Ser 1993; 10: 190–198.

    PubMed  CAS  Google Scholar 

  144. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735–1739.

    PubMed  CAS  Google Scholar 

  145. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39: 1–6.

    Article  PubMed  CAS  Google Scholar 

  146. Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 1995; 56: 87–93.

    PubMed  CAS  Google Scholar 

  147. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–432.

    Article  PubMed  CAS  Google Scholar 

  148. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1147–1153.

    PubMed  CAS  Google Scholar 

  149. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445–1452.

    Article  PubMed  CAS  Google Scholar 

  150. Quitkin FM, Stewart JW, McGrath PJ. Gender differences in treatment response. Am J Psychiatry 2001; 158: 1531–1533.

    Article  PubMed  CAS  Google Scholar 

  151. Quitkin FM, Stewart JW, McGrath PJ, et al. Are there differences between women’s and men’s antidepressant responses? Am J Psychiatry 2002; 159: 1848–1854.

    Article  PubMed  Google Scholar 

  152. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308–315.

    Article  PubMed  CAS  Google Scholar 

  153. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51: 237–254.

    Article  PubMed  CAS  Google Scholar 

  154. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401.

    PubMed  CAS  Google Scholar 

  155. Settle EC, Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998; 59 Suppl 4: 32–36.

    Google Scholar 

  156. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 Suppl 6: 12–21.

    Google Scholar 

  157. Lineberry TW, Peters GE, Jr., Bostwick JM. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001; 76: 664–666.

    PubMed  CAS  Google Scholar 

  158. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002; 63: 10–17.

    PubMed  CAS  Google Scholar 

  159. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280–294.

    Article  PubMed  CAS  Google Scholar 

  160. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl 1: 24–32.

    Article  Google Scholar 

  161. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997; 58 Suppl 6: 26–31.

    Google Scholar 

  162. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55: 104–108.

    PubMed  CAS  Google Scholar 

  163. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154: 1760–1762.

    PubMed  CAS  Google Scholar 

  164. Einarson A, Fatoye B, Sarkar M, et al. Prenancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728–1730.

    Article  PubMed  CAS  Google Scholar 

  165. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311–315.

    PubMed  CAS  Google Scholar 

  166. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996; 57: 39–44.

    PubMed  CAS  Google Scholar 

  167. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry 1987; 48: 244–245.

    PubMed  CAS  Google Scholar 

  168. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47: 375–377.

    PubMed  Google Scholar 

  169. Ehrentraut S, Rothenhausler HB, Gerbes AL, et al. Acute liver failure in nefazodone therapy? A case report [in German]. Nervenarzt 2002; 73: 686–689.

    Article  PubMed  CAS  Google Scholar 

  170. de Boer T, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988; 27: 399–408.

    Google Scholar 

  171. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57: 19–25.

    PubMed  Google Scholar 

  172. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–918.

    Article  PubMed  CAS  Google Scholar 

  173. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 86: 369–374.

    Article  Google Scholar 

  174. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332–1333.

    Article  PubMed  Google Scholar 

  175. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry 1998; 59: 233–235.

    Article  PubMed  CAS  Google Scholar 

  176. Benson BE, Mathiason M, Dahl B, et al. Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med 2000; 18: 587–592.

    Article  PubMed  CAS  Google Scholar 

  177. de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 2001; 56: 258–261.

    PubMed  Google Scholar 

  178. Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997; 35: 321–324.

    Article  PubMed  CAS  Google Scholar 

  179. Storrow AB. Bupropion overdose and seizure. Am J Emerg Med 1994; 12: 183–184.

    Article  PubMed  CAS  Google Scholar 

  180. Spiller HA, Ramoska EA, Krenzelok EP, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994; 12: 43–45.

    Article  PubMed  CAS  Google Scholar 

  181. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135: 423–433.

    PubMed  CAS  Google Scholar 

  182. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57: 1583–1588.

    Article  PubMed  CAS  Google Scholar 

  183. Dostert P, Benedetti MS, Poggest I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7: S23–S35.

    Article  PubMed  CAS  Google Scholar 

  184. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39: 413–427.

    Article  PubMed  CAS  Google Scholar 

  185. Ohman D, Cherma MD, Norlander B, Bengstosson F. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 2003; 25: 174–182.

    Article  PubMed  Google Scholar 

  186. Burrows GD, Maguire KP, Norman TR. Antidepressant efficiacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59: 4–7.

    PubMed  CAS  Google Scholar 

  187. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000; 61 Suppl 10: 31–38.

    Google Scholar 

  188. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28–34.

    Article  PubMed  CAS  Google Scholar 

  189. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001; 70: 261–269.

    Article  PubMed  CAS  Google Scholar 

  190. Andreoli V, Caillard V, Deo R, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002; 22: 393–399.

    Article  PubMed  CAS  Google Scholar 

  191. Montgomery S, Fuerguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003; 23: 45–50.

    Article  PubMed  CAS  Google Scholar 

  192. Bymaster FP, Carter PA, DeLapp NW, Calligaro DO, Felder CC. Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo. Brain Res 2001; 916: 165–171.

    Article  PubMed  CAS  Google Scholar 

  193. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21: 516–521.

    Article  PubMed  CAS  Google Scholar 

  194. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52: 386–392.

    Article  PubMed  CAS  Google Scholar 

  195. Krishnan KR. Clinical experience with substance P receptor (NK1 antagonists in depression. J Clin Psychiatry 2003; 63: 25–29.

    Google Scholar 

  196. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984; 19: 509–516.

    PubMed  CAS  Google Scholar 

  197. Fox H, Gibas J. Synthetic tuberculostats. VII. Monoalkyl derivatives of isonicotinylhydrazine. J Org Chem 1953; 18: 994–1002.

    Article  CAS  Google Scholar 

  198. Selikoff IJ, Robitzek EH, Orenstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA 1952; 150: 973–980.

    Article  CAS  Google Scholar 

  199. Loomers HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 1957; 8: 129–141.

    Google Scholar 

  200. Kline NS. Clinical experience with iproniazid (MARSILID). J Clin Exp Pyschopathol 1958; 19: 72–78.

    CAS  Google Scholar 

  201. Zeller EA, Barsky JR, Fouts W, et al. Influence of isonicotinic acid hydrazide (INH) and 1- isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 1952; 8: 349–350.

    Article  CAS  Google Scholar 

  202. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase AB inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 2002; 43: 999–1005.

    Article  PubMed  CAS  Google Scholar 

  203. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19: 411–426.

    Article  PubMed  CAS  Google Scholar 

  204. Youdim MB, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranylcypromine (‘Parnate’) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 1979; 9: 377–382.

    Article  PubMed  CAS  Google Scholar 

  205. Sherry-McKenna RL, Baker GB, Mousseau DD, Coutts RT, Dewhurst WG. 4-methoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration. Biol Psychiatry 1992; 31: 881–888.

    PubMed  CAS  Google Scholar 

  206. Sherry RL, Rauw G, McKenna KF, Paetsch PR, Coutts RT, Baker GB. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. J Affect Disord 2000; 61: 23–29.

    Article  PubMed  CAS  Google Scholar 

  207. Lang A, Geissler HE, Mutschler E. Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers [in German]. Arzneimittelforschung 1979; 29: 154–157.

    PubMed  CAS  Google Scholar 

  208. Spahn-Langguth H, Hahn G, Mutschler E, Mohrke W, Langguth P. Enantiospecific high-performance liquid chromatographic assay with fluoroscence detection for the monoamine oxidase ihibitor tranylcypromine and its applicability in pharmacokinetic studies. J Chromatogr 1992; 584: 229–237.

    Article  PubMed  CAS  Google Scholar 

  209. Livingston MG, Livingston HM. Monoamine oxidase inhibitors: an update on drug interactions. Drug Saf 1996; 14: 219–227.

    Article  PubMed  CAS  Google Scholar 

  210. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226–247.

    Article  PubMed  CAS  Google Scholar 

  211. Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R. Moclobemide versus clomipramine in endogenous depression: a double-blind randomised clinical trial. Br J Psychiatry 1992; 160: 519–524.

    Article  PubMed  CAS  Google Scholar 

  212. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 1997; 247: 113–119.

    Article  PubMed  CAS  Google Scholar 

  213. van Vliet IM, Westenberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine: a double blind placebo controlled study. Psychopharmacology (Berl) 1993; 112: 483–489.

    Article  Google Scholar 

  214. Haefely W, Burkard WP, Cesura AM, et al. Biochemistry and pharmacology of moclobemide, a prototype Rima. Psychopharmacology (Berl) 1992; 106 Suppl:S6–S 14.

    Google Scholar 

  215. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150: 118–123.

    PubMed  CAS  Google Scholar 

  216. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129–137.

    Article  PubMed  CAS  Google Scholar 

  217. McGrath PJ, Stewart JW, Harrison WM, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992; 12: 197–202.

    Article  PubMed  CAS  Google Scholar 

  218. Vallejo J, Gasto C, Catalan R, Salamero M. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987; 151: 639–642.

    Article  PubMed  CAS  Google Scholar 

  219. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–916.

    PubMed  CAS  Google Scholar 

  220. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155–1166.

    Article  PubMed  CAS  Google Scholar 

  221. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990; 47: 935–941.

    Article  PubMed  CAS  Google Scholar 

  222. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185–219.

    Article  PubMed  CAS  Google Scholar 

  223. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985; 142: 619–623.

    PubMed  CAS  Google Scholar 

  224. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986; 143: 345–348.

    PubMed  CAS  Google Scholar 

  225. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195–198.

    PubMed  CAS  Google Scholar 

  226. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992; 49: 290–300.

    PubMed  CAS  Google Scholar 

  227. Stein G. Drug treatment of the personality disorders. Br J Psychiatry 1992; 161: 167–184.

    Article  PubMed  CAS  Google Scholar 

  228. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993; 150: 1843–1848.

    PubMed  CAS  Google Scholar 

  229. Nurnberg HG, Levine PE. Spontaneous remission of MAOI-induced anorgasmia. Am J Psychiatry 1987; 144: 805–807.

    PubMed  CAS  Google Scholar 

  230. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese [letter]. Lancet 1963; 2: 733–734.

    Article  PubMed  CAS  Google Scholar 

  231. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349–365.

    Article  PubMed  CAS  Google Scholar 

  232. Hyman S. Toxic side effects of psychotropic medications and their management. In: Hyman S, Tesar G, eds. Manual of Psychiatric Emergencies. Boston, Mass: Little, Brown and Co., 1994: 204–217, 304–322.

    Google Scholar 

  233. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954–955.

    PubMed  CAS  Google Scholar 

  234. Creelman WL, Ciraulo DA. Monoamine oxidase inhibitors (MAOIS). In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, eds. Drug Interactions in Psychiatry. Baltimore, Md: Williams and Wilkins, 1995: 430.

    Google Scholar 

  235. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984; 13: 1137–1144.

    Article  PubMed  CAS  Google Scholar 

  236. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856–857.

    Article  PubMed  CAS  Google Scholar 

  237. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995: 1081.

    Google Scholar 

  238. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58: 23–29.

    PubMed  Google Scholar 

  239. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000; 61: 10–12.

    PubMed  Google Scholar 

  240. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45–49.

    Article  PubMed  CAS  Google Scholar 

  241. Debonnel G, Gobbi G, Turcotte J, et al. The a2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at: 39th Annual Meeting of the American College of Neuropsycho-pharmacology; San Juan, Puerto Rico; 2000.

    Google Scholar 

  242. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Biol Psychiatry 2002; 51: 183–188.

    Article  PubMed  CAS  Google Scholar 

  243. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996; 16: 80–81.

    Article  PubMed  CAS  Google Scholar 

  244. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58: 137–145.

    Article  PubMed  CAS  Google Scholar 

  245. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety 1998; 7: 73–75.

    Article  PubMed  CAS  Google Scholar 

  246. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry 2000; 61: 403–408.

    Article  PubMed  CAS  Google Scholar 

  247. Nelson JC, Mazure CM, Bowers MB, Jr., Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303–307.

    Article  PubMed  CAS  Google Scholar 

  248. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151: 1372–1374.

    PubMed  CAS  Google Scholar 

  249. Rothschild BS. Fluoxetine-nortiptyline therapy of treatment-resistant major depression in a geriatric patient. J Geriatr Psychiatry Neurol 1994; 7: 137–138.

    PubMed  CAS  Google Scholar 

  250. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 1997; 5: 84–90.

    Article  PubMed  CAS  Google Scholar 

  251. de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252–256.

    Article  PubMed  Google Scholar 

  252. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepresant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983; 40: 1327–1334.

    Article  PubMed  Google Scholar 

  253. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387–393.

    Article  PubMed  CAS  Google Scholar 

  254. Gray EG. Severe depression: a patient’s thoughts. Br J Psychiatry 1983; 143: 319–322.

    Article  PubMed  CAS  Google Scholar 

  255. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983; 40: 1335–1342.

    Article  PubMed  CAS  Google Scholar 

  256. Graham PM. Drug combination for chronic depression. Br J Psychiatry 1984; 145: 214.

    Article  PubMed  CAS  Google Scholar 

  257. Pope HG, Jr., McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988; 145: 1292–1294.

    PubMed  Google Scholar 

  258. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–86.

    Article  PubMed  CAS  Google Scholar 

  259. Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Psychopharmacol (Oxf) 1999; 19: 164–171.

    CAS  Google Scholar 

  260. Jacobsen FM. A possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217–220.

    PubMed  CAS  Google Scholar 

  261. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269–271.

    PubMed  CAS  Google Scholar 

  262. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997; 87: 534–537.

    PubMed  CAS  Google Scholar 

  263. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998; 18: 465–469.

    Article  PubMed  CAS  Google Scholar 

  264. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448–452.

    Article  PubMed  CAS  Google Scholar 

  265. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59: 664–668.

    Article  PubMed  CAS  Google Scholar 

  266. Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 1387–1395.

    Google Scholar 

  267. Wharton RN, Perel JM, Dayton PG, Malitz SM. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971; 127: 1619–1625.

    PubMed  CAS  Google Scholar 

  268. Fawcett JA, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Psychopharmacol (Oxf) 1991; 11: 127–132.

    CAS  Google Scholar 

  269. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996; 57: 72–76.

    Article  PubMed  CAS  Google Scholar 

  270. Bader GM, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol 1998; 18: 255–256.

    Article  PubMed  CAS  Google Scholar 

  271. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second-generation antidepressants: a case series. Depress Anxiety 1998; 7: 89–91.

    Article  PubMed  CAS  Google Scholar 

  272. Postolache TT, Rosenthal RN, Hellerstein DJ, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999; 60: 123–124.

    Article  PubMed  CAS  Google Scholar 

  273. Lavretsky H, KUmar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9: 298–303.

    PubMed  CAS  Google Scholar 

  274. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 781–823.

    Article  PubMed  CAS  Google Scholar 

  275. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002; 59: 409–416.

    Article  PubMed  Google Scholar 

  276. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61: 378–381.

    Article  PubMed  CAS  Google Scholar 

  277. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy [letter]. J Clin Psychopharmacol 2003; 23: 207–209.

    Article  PubMed  Google Scholar 

  278. Prange AJ Jr, et al. Hormonal alteration of imipramine response: a review. In: Sachar EJ, ed. Hormones, Behavior, and Psychopathology. New York, NY: Raven Press; 1976.

    Google Scholar 

  279. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26: 229–233.

    Article  PubMed  CAS  Google Scholar 

  280. Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3, and antidepressants in depression. J Int Med Res 1979; 7: 138–146.

    PubMed  CAS  Google Scholar 

  281. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry 1970; 126: 1667–1669.

    PubMed  CAS  Google Scholar 

  282. Ogura C, Okuma T, Uchida Y, Imai S, Yogi H. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28: 179–186.

    PubMed  CAS  Google Scholar 

  283. Goodwin FK, Prange A, Post R, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982; 139: 34–38.

    PubMed  CAS  Google Scholar 

  284. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine: augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163: 574–578.

    Article  PubMed  CAS  Google Scholar 

  285. Crowe D, Collins JP, Rosse RB. Thyroid hormone supplementation of fluoxetine treatment [letter]. J Clin Psychopharmacol 1990; 10: 150–151.

    Article  PubMed  CAS  Google Scholar 

  286. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry 1991; 159: 866–867.

    Article  PubMed  CAS  Google Scholar 

  287. Joffe RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 1992; 37: 48–50.

    PubMed  CAS  Google Scholar 

  288. Gitlin MJ, Weiner H, Farbanks L, Hershman JM, Friedfeld N. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord 1987; 13: 267–272.

    Article  PubMed  CAS  Google Scholar 

  289. Targum SD, Greenberg RD, Harmon RL, Kessler K, Salerian AJ, Fram DH. Thyroid hormone and the TRH stimulation test in refractory depression. J Clin Psychiatry 1984; 45: 345–346.

    PubMed  CAS  Google Scholar 

  290. Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation: a pilot study. J Affect Disord 1998; 49: 235–239.

    Article  PubMed  CAS  Google Scholar 

  291. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444–455.

    Article  PubMed  CAS  Google Scholar 

  292. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–1622.

    Article  PubMed  CAS  Google Scholar 

  293. Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 105–111.

    Article  PubMed  Google Scholar 

  294. de Novaes Soares C, Almeida O, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58: 529–534.

    Article  Google Scholar 

  295. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183: 414–420.

    Article  PubMed  CAS  Google Scholar 

  296. Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002; 63: 745–748.

    Google Scholar 

  297. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475–484.

    Article  PubMed  CAS  Google Scholar 

  298. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996; 347: 930–933.

    Article  PubMed  CAS  Google Scholar 

  299. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology (Berl) 1999; 146: 108–110.

    Article  CAS  Google Scholar 

  300. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977; 4: 31–47.

    CAS  Google Scholar 

  301. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981; 31: 134–140.

    PubMed  CAS  Google Scholar 

  302. Pearce J, Hawton K, Blake F, et al. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res 1997; 42: 177–186.

    Article  PubMed  CAS  Google Scholar 

  303. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med 1999; 61: 676–697.

    PubMed  CAS  Google Scholar 

  304. Montgomery JC, Brincat M, Tapp A, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987; 1: 297–299.

    Article  PubMed  CAS  Google Scholar 

  305. Kaliber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979; 36: 550–554.

    Article  Google Scholar 

  306. Haines CJ, Yim SF, Chung TKH, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas 2003; 44: 207–214.

    Article  PubMed  CAS  Google Scholar 

  307. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997; 5: 97–106.

    PubMed  CAS  Google Scholar 

  308. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003; 17: 139–147.

    Article  PubMed  CAS  Google Scholar 

  309. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349: 535–545.

    Article  PubMed  CAS  Google Scholar 

  310. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254–3263.

    Article  PubMed  CAS  Google Scholar 

  311. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534.

    Article  PubMed  CAS  Google Scholar 

  312. Schultz V, Haensel R, Tyler VE. Rational Phytotherapy. Berlin: Springer, 1998.

    Book  Google Scholar 

  313. Assemi M. Herbs affecting the central nervous system: gingko, kava, St. John’s wort, and valerian. Clin Obstet Gynecol 2001; 44: 824–835.

    Article  PubMed  CAS  Google Scholar 

  314. De Smet P. Herbal remedies. N Engl J Med 2002; 347: 2046–2056.

    Article  PubMed  Google Scholar 

  315. Bilia AR, Gallori S, Vincieri FF. St. John’s wort and depression: efficacy, safety and tolerability—an update. Life Sci 2002; 70: 3077–3096.

    Article  PubMed  CAS  Google Scholar 

  316. Chatterjee S, Filippov V, Lishko P, et al. Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 1999; 65: 2395–2405.

    Article  PubMed  CAS  Google Scholar 

  317. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999; 319: 1534–1538.

    Article  PubMed  CAS  Google Scholar 

  318. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John’s wort in major depression: a randomized controlled trial. JAMA 2001; 285: 1978–1986.

    Article  PubMed  CAS  Google Scholar 

  319. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136: 42–53.

    PubMed  Google Scholar 

  320. Woelk H. Comparison of St. John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 2000; 321: 536–539.

    Article  CAS  Google Scholar 

  321. Gaster B, Holroyd J. St. John’s wort for depression: a systematic review. Arch Intern Med 2000; 160: 152–156.

    Article  PubMed  CAS  Google Scholar 

  322. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159: 1361–1366.

    Article  PubMed  CAS  Google Scholar 

  323. Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. Journal of Geriatric Psychiatry Neurology 1999; 12: 7–10.

    Article  CAS  Google Scholar 

  324. Prost N, Tichadou L, Rodor F, Nguyen N, David JM, Jean-Pastor MJ. [St. Johns wortvenlafaxine interaction]. Presse Med 2000; 29: 1285–1286.

    PubMed  CAS  Google Scholar 

  325. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601–1608.

    Article  PubMed  CAS  Google Scholar 

  326. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St. John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349–356.

    Article  PubMed  CAS  Google Scholar 

  327. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother 2000; 34: 1013–1016.

    Article  PubMed  CAS  Google Scholar 

  328. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001; 71: 239–241.

    Article  PubMed  CAS  Google Scholar 

  329. Yue QY, Bergquist C, Gerden B. Safety of St. John’s wort (Hypericum perforatum). Lancet 2000; 355: 576–577.

    Article  PubMed  CAS  Google Scholar 

  330. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St. John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317–326.

    PubMed  CAS  Google Scholar 

  331. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338–345.

    Article  PubMed  CAS  Google Scholar 

  332. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John’s wort for depression: an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253–258.

    Article  PubMed  CAS  Google Scholar 

  333. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients: a meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl) 2002; 164: 301–308.

    Article  CAS  Google Scholar 

  334. Spira JL. Comparison of St. John’s Wort and imipramine: study design casts doubt on value of St. John’s wort in treating depression. BMJ 2001; 322:493; author reply, 494.

    Google Scholar 

  335. Effect of Hypericum perforatum (St. John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002; 287: 1807–1814.

    Article  Google Scholar 

  336. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002; 76: 1158S–1161S.

    PubMed  CAS  Google Scholar 

  337. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl 1994; 154: 15–18.

    Article  PubMed  CAS  Google Scholar 

  338. Bressa GM. S-adenoxyl-methionine (SAMe) as antidepressant: metanalysis of clinical studies. Acta Neurol Scand 1994; 154: 7–14.

    Article  CAS  Google Scholar 

  339. Pancheri P, Racagni G, Delle Chiaie R, Popoli M. Recent experimental and clnical findings on the efficacy and safety of ademetionine in the pharmacological treatment of depression. G Ital Psicopat 1997; 3: 1–23.

    Google Scholar 

  340. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002; 76: 1172S–1176S.

    Google Scholar 

  341. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parental S-adenosyl-L-methionine. Psychiatry Res 1995; 56: 295–297.

    Article  PubMed  CAS  Google Scholar 

  342. Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351: 1213.

    Article  PubMed  CAS  Google Scholar 

  343. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996; 38: 35–46.

    Article  PubMed  CAS  Google Scholar 

  344. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149–155.

    Article  PubMed  CAS  Google Scholar 

  345. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinic symptoms of depression. Lipids 1996; 31: 157–161.

    Article  Google Scholar 

  346. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913–919.

    Article  PubMed  CAS  Google Scholar 

  347. Calabrese JR, Rapport DJ, Shelton MD. Fish oils and bipolar disorder: a promising but untested treatment [commentary]. Arch Gen Psychiatry 1999; 56: 413–414.

    Article  PubMed  CAS  Google Scholar 

  348. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407–412.

    Article  PubMed  CAS  Google Scholar 

  349. Stoll AL, Marangell LB. In reply [commentary]. Arch Gen Psychiatry 1999; 56: 415–416.

    Article  Google Scholar 

  350. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL. Drug interactions in psychiatry. Baltimore, Md: Williams and Wilkins; 1995: 430.

    Google Scholar 

  351. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19: 23S–35S.

    Article  PubMed  CAS  Google Scholar 

  352. Burke WJ, McArthur-Miller DA. Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry 2001; 62: 38–42.

    PubMed  CAS  Google Scholar 

  353. Dinan TG. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry 2001; 62: 48–52.

    PubMed  CAS  Google Scholar 

  354. Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs 2001; 61: 2221–2230.

    Article  PubMed  CAS  Google Scholar 

  355. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2001; 62: 43–47.

    PubMed  Google Scholar 

  356. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989; 9: 397–402.

    Article  PubMed  CAS  Google Scholar 

  357. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry 1999; 60: 191–193.

    Article  PubMed  CAS  Google Scholar 

  358. Nestler EJ, Hyman SE, Malenka RC. Molecular neropharmacology: a foundation for clinical neuroscience. New York: McGraw-Hill Companies, Inc., 2001: 539.

    Google Scholar 

Download references

Authors
  1. Domenic A. Ciraulo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucy Tsirulnik-Barts MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard I. Shader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David J. Greenblatt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Psychiatry, Boston University School of Medicine, Boston, MA, USA

    Domenic A. Ciraulo MD

  2. Division of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA

    Richard I. Shader MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ciraulo, D.A., Tsirulnik-Barts, L., Shader, R.I., Greenblatt, D.J. (2004). Clinical Pharmacology and Therapeutics of Antidepressants. In: Ciraulo, D.A., Shader, R.I. (eds) Pharmacotherapy of Depression. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-792-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-792-5_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6172-6

  • Online ISBN: 978-1-59259-792-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation